Cargando…
Electronic Health Records to Rapidly Assess Biosimilar Uptake: An Example Using Insulin Glargine in a Large U.S. Nursing Home Cohort
Large healthcare administrative databases, like Medicare claims, are a common means to evaluate drug policies. However, administrative data often have a lag time of months to years before they are available to researchers and decision-makers. Therefore, administrative data are not always ideal for t...
Autores principales: | Hayes, Kaleen N., Mor, Vincent, Zullo, Andrew R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114471/ https://www.ncbi.nlm.nih.gov/pubmed/35600866 http://dx.doi.org/10.3389/fphar.2022.855598 |
Ejemplares similares
-
Pharmacokinetic and pharmacodynamic similarity evaluation between an insulin glargine biosimilar product and Lantus(®) in healthy subjects: Pharmacokinetic parameters of both parent insulin glargine and M1 were used as endpoints
por: Wang, Yiya, et al.
Publicado: (2022) -
2170. The National Burden of Pneumonia and Influenza in U.S. Nursing Homes, 2013–2015
por: Mcconeghy, Kevin, et al.
Publicado: (2018) -
Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2021) -
Trends in COVID-19-related Medication Use in US Nursing Homes, 2018-2022
por: Zhang, Yuan, et al.
Publicado: (2023) -
Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)